CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

GLPG5101 Produces Responses With Manageable Safety in R/R NHL, MCL

December 9th 2025

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma

December 8th 2025

AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.

Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma

December 6th 2025

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.

FDA Approves Liso-Cel for Relapsed/Refractory Marginal Zone Lymphoma

December 4th 2025

The FDA approved liso-cel for relapsed/refractory MZL after 2 prior lines of therapy.

Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025

December 3rd 2025

Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

NICE Recommends Obe-Cel for Adult R/R B-ALL

December 1st 2025

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

European Commission Approves Liso-Cel for R/R Mantle Cell Lymphoma

November 25th 2025

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Sequential ICV/IV C7R-GD2 CAR T-Cell Therapy Is Better Tolerated in Pediatric CNS Tumors

November 24th 2025

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer

November 22nd 2025

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma

November 22nd 2025

B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.

Adjuvant Satri-Cel Displays Preliminary Activity in Pancreatic Ductal Adenocarcinoma

November 14th 2025

Satri-cel displayed preliminary efficacy when used as adjuvant treatment in patients with pancreatic ductal adenocarcinoma.

MB-105 Receives FDA RMAT Designation in CD5+ R/R T-Cell Lymphoma

November 13th 2025

The FDA granted RMAT designation to MB-105 for CD5-positive relapsed/refractory T-cell lymphoma.

Sequential CAR T-Cell Therapy and ASCT Yields Durable Remissions in Ph-Negative B-ALL

November 12th 2025

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma

November 11th 2025

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

Looking Ahead to the Future of CAR T Therapy for B-Cell Lymphoma

October 31st 2025

Panelists discuss how CAR T therapy represents the best curative option for relapsed B-cell lymphoma and how community oncologists must prepare for the inevitable expansion of cellular therapies across multiple disease areas.

Considerations for Patients With B-Cell Lymphoma CAR T to Be Treated in the Community Setting

October 24th 2025

Panelists discuss how expanding CAR T to more community sites requires adequate volume, intensive care unit support, and subspecialty backup, while recognizing that not every center should administer this therapy.

Additional Resources Needed in the Community Setting to Manage CAR T in Patients With B-Cell Lymphoma

October 24th 2025

Panelists discuss how community practices need better systems for disseminating CAR T care guidelines to all team members and clearer vaccination schedules for patients post CAR T.

Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments

October 22nd 2025

Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

Arlo-Cel Delivers High, Durable Responses With Manageable Safety in R/R Myeloma

October 22nd 2025

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

BTK Inhibitors, CAR T-Cell Therapies, and JAK Inhibitors Refine Hematologic Oncology Standards

October 21st 2025

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.